Advertisement

The Superobese Patient

  • Michel SuterEmail author
Chapter
  • 34 Downloads

Abstract

Like cancer and other chronic and progressive medical conditions, obesity has traditionally been divided into different stages according to the severity of the disease. Although the World Health Organization (WHO) recognizes that BMI may not always express similar degrees of fatness between individuals, this organization defines obesity as abnormal or excessive fat accumulation that may impair health, with a body mass index of 30 kg/m2 as a threshold [1]. The risks associated with obesity are continuous and increase with disease severity. WHO recognizes three classes of obesity according to the body mass index (BMI). Class 1 obesity refers to patients with modest obesity and a BMI between 30 and 34,9 kg/m2, class 2 includes patients with a BMI between 35 and 39,9 kg/m2, and class 3 refers to patients with a BMI ≥ 40 kg/m2. In the nonspecialized literature, the latter patients are offered referred to as massively obese, or extremely obese. In bariatric medicine, which essentially deals with patients in the WHO class 2 and 3 categories, it is useful to further divide morbid obesity into more classes. This may be helpful in selecting patients for various bariatric procedures, for specific surgical approaches, for preoperative patient preparation and/or weight loss, etc. It is also useful to have categories encompassing patient groups that can reasonably be compared between each other both regarding risks, results of surgery, morbidity and mortality, or any other specific issue. The superobese patient is defined arbitrarily has having a BMI ≥ 50 kg/m2. Other terms are being used for even more severe sub-categories such as patients with BMI > 60 (super-super-obese) or above 70 (mega-obese).

References

  1. 1.
    World health Organization. www.who.int/mediacentre/factsheets/fs311/en/. Accessed 13 Sept 2016.
  2. 2.
    Antonini-Canterin F, Mateescu AD, Vriz O, La Carrubba S, Di Bello V, Carerj S, Zito C, Sparacino L, Marzano B, Usurelu C, Ticulescu R, Ginghina C, Nicolosi GL, Popescu BA. Cardiac structure and function and insulin resistance in morbidly obese patients: does superobesity play an additional role? Cardiology. 2014;127:144–51.CrossRefGoogle Scholar
  3. 3.
    Kakarla VR, Nandipati K, Lalla M, Castro A, Merola S. Are laparoscopic bariatric procedures safe in superobese (BMI ≥ 50 kg/m2) patients? An NSQIP data analysis. Surg Obes Relat Dis. 2011;7:452–8.CrossRefGoogle Scholar
  4. 4.
    Muñoz S, Nowzaradan Y, Varon J. Extreme obesity in the intensive care unit: the malignant obesity hypoventilation syndrome. J Intensive Care Med. 2013;28:134–5.CrossRefGoogle Scholar
  5. 5.
    Matthew R, Castriotta RJ. High hypopnea/apnea ratio (HAR) in extreme obesity. J Clin Sleep Med. 2014;10:391–6.CrossRefGoogle Scholar
  6. 6.
    Lopez PP, Stefan B, Schulman CI, Byers PM. Prevalence of sleep apnea in morbidly obese patients who presented for weight loss surgery evaluation: more evidence for routine screening for obstructive sleep apnea before weight loss surgery. Am Surg. 2008;74:834–8.PubMedGoogle Scholar
  7. 7.
    Fabris SM, Faintuch J, Brienze SL, Brito GB, Sitta IS, Mendes EL, Fonseca IC, Cecconello I. Are knee and foot orthopedic problems more disabling in the superobese? Obes Surg. 2013;23:201–4.CrossRefGoogle Scholar
  8. 8.
    Marshall NE, Guild C, Cheng YW, Caughey AB, Halloran DR. Maternal superobesity and perinatal outcomes. Am J Obstet Gynecol. 2012;206:417.e1–6.CrossRefGoogle Scholar
  9. 9.
    Werner BC, Burrus MT, Browne JA, Brockmeier SF. Superobesity (body-mass index > 50 kg/m2) and complications after total shoulder arthroplasty: an incremental effect of increasing body mass index. J Shoulder Elb Surg. 2015;24:1868–75.CrossRefGoogle Scholar
  10. 10.
    Meller MM, Toossi N, Johanson NA, Gonzalez MH, Son MS, Lau EC. Risk and cost of 90-day complications in morbidly and superobese patients after total knee arthroplasty. J Arthroplast. 2016;31:2091–8.CrossRefGoogle Scholar
  11. 11.
    Livingston EH, Arterburn D, Schifftner TL, Henderson WG, DePalma RG. National surgical quality improvement program analysis of bariatric operations: modifiable risk factors contribute to bariatric surgical adverse outcomes. J Am Coll Surg. 2006;203:625–33.CrossRefGoogle Scholar
  12. 12.
    Fernandez AZ, DeMaria EJ, Tichansky DS, Kellum JM, Wolfe LG, Meador J, Sugerman HJ. Multivariate analysis of risk factors for death following gastric bypass for treatment of morbid obesity. Ann Surg. 2004;239:698–702.CrossRefGoogle Scholar
  13. 13.
    Fazylov RM, Savel RH, Horovitz JH, Pagal MK, Coppa GF, Nicastro J, Lazzaro RS, Macura JM. Association of super-obesity and male gender with elevated mortality in patients undergoing the duodenal switch procedure. Obes Surg. 2005;15:618–23.CrossRefGoogle Scholar
  14. 14.
    Dresel A, Kuhn JA, McCarthy TM. Laparoscopic Roux-en-Y gastric bypass in morbidly obese and super morbidly obese patients. Am J Surg. 2004;187:230–2.CrossRefGoogle Scholar
  15. 15.
    Dayer-Jankechova A, Fournier P, Allemann P, Suter M. Complications after laparoscopic Roux-en-Y gastric bypass in 1573 consecutive patients: are there predictors? Obes Surg. 2016;26:12–20.CrossRefGoogle Scholar
  16. 16.
    Suter M, Calmes JM, Paroz A, Romy S, Giusti V. Results of Roux-en-Y gastric bypass in morbidly versus superobese patients: similar body weight loss, correction of comorbidities, and improvement of quality of life. Arch Surg. 2009;144:312–8.CrossRefGoogle Scholar
  17. 17.
    Marino JL, Stapleton RD, Wang M, Day AG, Cahill NE, Dixon AE, Suratt BT, Heyland DK. Extreme obesity and outcomes in critically ill patients. Chest. 2011;140:1198–206.CrossRefGoogle Scholar
  18. 18.
    Magro DO, Geloneze B, Delfini R, Pareja BC, Callebas F, Pareja JC. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18:648–51.CrossRefGoogle Scholar
  19. 19.
    Topart P, Becouarn G, Ritz P. Weight loss is more sustained after biliopancreatic diversion with duodenal switch than Roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis. 2013;9:526–30.CrossRefGoogle Scholar
  20. 20.
    Christou NV, Look D, MacLean LD. Weight gain after short-and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg. 2006;244:734–40.CrossRefGoogle Scholar
  21. 21.
    Biron S, Hould FS, Lebel S, Marceau S, Lescelleur O, Simard S, Marceau P. Twenty years of biliopancreatic diversion. What is the goal of surgery? Obes Surg. 2004;14:160–4.CrossRefGoogle Scholar
  22. 22.
    Sovik TT, Taha O, Aasheim ET, Engström M, Kristinsson J, Björkman S, Schou CF, Lönroth H, Mala T, Olbers T. Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic duodenal switch for superobesity. Br J Surg. 2010;97:160–6.CrossRefGoogle Scholar
  23. 23.
    Risstad H, Sovik TT, Engström M, Aasheim ET, Fagerland MW, Olsen MF, Kristinsson JA, LeRoux CW, Bohmer T, Birkeland KI, Mala T, Olbers T. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg. 2015;150:352–61.CrossRefGoogle Scholar
  24. 24.
    Huerta S, Li Z, Anthony T, Livingston EH. Feasibility of a supervised inpatient low-calorie diet program for massive weight loss prior to RYGB in superobese patients. Obes Surg. 2010;20:173–80.CrossRefGoogle Scholar
  25. 25.
    Orlando G, Gervasi R, Luppino IM, Vitale M, Amato B, Silecchia G, Puzziello A. The role of a multidisciplinary approach in the choice of the best surgery approach in a super-super-obesity case. Int J Surg. 2014;12(suppl 1):S103–6.CrossRefGoogle Scholar
  26. 26.
    Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, van Dielen F, Wiezer R, Janssen I, Kramer M, Thorell A. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass. A randomized multicenter study. Arch Surg. 2011;146:1300–5.CrossRefGoogle Scholar
  27. 27.
    Zerrweck C, Maunoury V, Caiazzo R, Branche J, Dezfoulian G, Bulois P, Verkindt H, Pigeyre M, Arnalsteen L, Pattou F. Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients. Obes Surg. 2012;22:777–82.CrossRefGoogle Scholar
  28. 28.
    Coffin B, Maunoury V, Pattou F, Xébuterne X, Schneider S, Coupaye M, et al. Impact of intragastric balloon before laparoscopic gastric bypass on patients with superobesity: a randomized multicenter study. Obes Surg. 2016;27:902.  https://doi.org/10.1007/s11695-016-2383-x.CrossRefGoogle Scholar
  29. 29.
    Collins J, McCloskey C, Titchner R, Goodpaster B, Hoffman M, Hauser D, Wilson M, Eid G. Preoperative weight loss in high-risk superobese bariatric patients: a computed tomography-based analysis. Surg Obes Relat Dis. 2011;7:480–5.CrossRefGoogle Scholar
  30. 30.
    Sekino Y, Imajo K, Sakai E, Uchiyama T, Iida H, Endo H, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med. 2011;50:2449–55.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of SurgeryRiviera-Chablais HospitalAigle-MontheySwitzerland
  2. 2.Department of Visceral SurgeryUniversity Hospital LausanneLausanneSwitzerland

Personalised recommendations